Experiences with
Chronic leukaemia5,770 public posts
Review article summarises management strategies for those with CLL harbouring complex karyotype
On 6 January 2025, the journal [i]BJ Haem[/i] published a review article titled [i]Management strategies for patients with lymphocytic leukaemia harbouring complex karyotype[/i] written by a team from Padua, Italy.
Additional insights from the 2023 Global Leukemia Experience Survey - CLL specific findings, unmet needs and recommendations for action
As chronic leukaemia progression is slower than acute, the symptom onset can be subtle and take years to have an impact on quality of life. Improving symptom awareness and early health seeking behaviour in the general population and targeted education for primary care clinicians may address this.
Want to take advantage of all our features? Just log in!
or
2025 Update about Chronic Lymphocytic Leukemia, its epidemiology, pathogenesis, diagnosis and therapy
[/i]
The full paper is a very thorough reference for those wanting to get a better understanding of what is currently understood about chronic lymphocytic leukemia and its treatment.
Financial Assistance for Patients with Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL)
Financial Assistance for Patients with Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL) https://www.lls.org/support-resources/financial-support/co-pay-assistance-program
If you are diagnosed with CLL or SLL, you may qualify for The Leukemia & Lymphoma Society's Co-Pay Assistance
Chemo-free treatment with acalabrutinib can benefit CLL/SLL patients never treated before: a plain language summary of the ELEVATE-TN study
Full Text (PDF)
https://www.tandfonline.com/doi/epdf/10.1080/14796694.2025.2455926
[i]The original article, [/i][i]“Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
[i] Abstract[/i]
[i][/i]
[i]The proliferation and survival of chronic lymphocytic leukemia (CLL) cells are heavily dependent on B-cell receptor (BCR) signaling and resistance to apoptosis.
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL
[i][/i]
[i]"Oral therapies targeting receptors in a blood cancer called chronic lymphocytic leukemia (CLL) have transformed outcomes with for those with this disease.
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Abstract report in New England Journal of Medicine Published February 5, 2025
No real new information here and I'm surprised anyone was recruited for this study as the control arm is chemoimmunotherapy and no account appears to have been taken for unmated IGHV or 17p/TP53 as the patients were
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying CLL patients with early treatment requirement
That long introduction brings me to the reason for this post, this article in Nature, brought to my attention by CLLerinOz https://www.nature.com/articles/s41375-024-02499-x
From the abstract, with my emphasis;
[i]The mutational status of immunoglobulin (IG) [/i][u][i]light chain genes [/i][/u][i]in chronic